 Blueprint Medicines NASDAQ:BPMC had its price objective hoisted by Deutsche Bank from 85.00 to 95.00 in a research report report published on Wednesday, The Fly reports. The brokerage currently has a buy rating on the biotechnology companys stock. A number of other research firms have also weighed in on BPMC. BidaskClub lowered shares of Blueprint ... 